Starlix (nateglinide) dosing, indications, interactions, adverse effects, and more

Sections

Sections nateglinide
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

60mg
120mg

Type 2 DM Monotherapy, or With Metformin

120 mg PO q8hr; 60 mg PO q8hr if patient near goal HbA1C

Take dose 1-30 minutes before meal

Safety & efficacy not established

Interaction Checker

Enter a drug name and nateglinide

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

1-10%

Increased uric acid (10%)

Dizziness (4%)

Arthropathy (3%)

Flu-like syndrome

Weight gain

Hypoglycemia (2%)

Frequency Not Defined

Diarrhea

Nausea

Contraindications

Documented hypersensitivity

Diabetic ketoacidosis, type I DM

Cautions

Patients with risk of severe hypoglycemia: elderly, malnourished, adrenal or pituitary insufficiency, hepatic insufficiency

Patients with stress due to infection, fever, trauma, or surgery

Not to be used in combination with an insulin secretagogue (eg, glyburide)

Not to be used as substitute for metformin monnotherapy but as adjunctive

Pregnancy & Lactation

Pregnancy Category: C

Lactation: unsafe

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Increases insulin secretion via binding K+ channels on beta islet cells. Reduces postprandial hyperglycemia. Amount of insulin released is dependent upon existing glucose levels.

Half-Life

1.2-3 hr

Duration

4 hr

Onset

Initial effect: 15 min

Max effect: 1-2 hr

Excretion

Urine:83%

Feces: 10%

Distribution

10 L

Other Information

Peak Plasma Time: < 1hr

Bioavailability: 72-75%

Protein Bound: 97-99%

Metabolism: by hepatic cytochrome P450 CYP2C9 (70%) & CYP3A4 (30%)

Metabolites: major metabolite M1 (20% potency of parent drug), & many other metabolites

Images

Patient Handout

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections nateglinide
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

nateglinide (Rx)